Immunicum Set to Expand Research and Development Facilities in the Netherlands
Immunicum is expanding its research and development activities in the Netherlands to further support its future growth. The Swedish biotech innovator in cancer treatment is moving its R&D activities into a new facility at the Leiden Bio Science Park, part of the Dutch Life Sciences and Health ecosystem and a key centre for research & development.
Immunicum has signed a long-term lease agreement with Kadans Science Partner for the Plus Ultra Leiden facility, the new R&D and business centre at Leiden Bio Science Park specifically focused on life sciences. Immunicum will house its entire Leiden-based operation at the centre. It will serve as Immunicum’s core research and development hub for its next-generation cell-based immunotherapies. The new location is expected to be fully operational in 2022.
Holland is one of Europe’s most vibrant life sciences research communities
Innovative companies like Immunicum find a welcoming home in the Netherlands, renowned for its connected communities, strategic location, opportunities for public-private partnerships and leading knowledge institutions.
‘This state-of-the-art facility in one of Europe’s most vibrant life sciences research communities is an integral part of our corporate strategy as it will enable us to rapidly and cost-effectively continue the development of potential transformative treatment options for cancer patients,’ stated Sven Rohmann, M.D., Ph.D., CEO of Immunicum. ‘We will establish this new facility as a centre of excellence, thereby gaining full control over crucial product development aspects of our cell-based therapies.’
Growing from strength to strength in state-of-the-art facility
Plus Ultra Leiden will be the new life sciences R&D and business centre at Leiden Bio Science Park, one of the vibrant life sciences communities in the Netherlands. This facility will stimulate the exchange of knowledge and stimulate collaboration between start-ups, scale-ups and large established companies and knowledge institutions. The new building is currently being constructed and is expected to be completed at the end of 2021.
‘We are happy to welcome Immunicum as the first tenant of Plus Ultra Leiden.’ said Chiel van Dijen, Commercial Director of Kadans Science Partner. ‘The company has a unique and promising immuno-oncology approach and makes a valuable addition to the ecosystem of Kadans and the Leiden Bio Science Park. We are looking forward to facilitating their further growth.’
About Immunicum
Immunicum is specialised in cell biology and develops novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients.
Source: Invest in Holland
